2023 World Conference on Lung Cancer (Posters)-EP12.01. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results

EP12.01. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results - PDF(Abstract)

Back to course

Pdf Summary

This study presented the updated results of a real-world study on the use of aumolertinib as first-line therapy for elderly patients with epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). EGFR-tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for NSCLC patients, but elderly patients often have impaired organ function and multiple diseases that can impact their response to treatment. The study aimed to assess the efficacy and safety of aumolertinib in this patient population.<br /><br />The study included 86 patients with stage IIA-IVB EGFR NSCLC who received aumolertinib alone as their first-line therapy. The primary endpoint was the objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and safety.<br /><br />The results showed that the overall ORR was 74.4%, and the DCR was 97.7%. There were no statistical differences in ORR and DCR between patients older than 65 and those younger than 65. The median PFS was 25 months for all patients, and the 2-year PFS rate was similar in both age groups. The overall adverse event rate was 50%, with a low incidence of grade 3 adverse events in both age groups.<br /><br />The study concluded that aumolertinib as first-line therapy showed excellent and encouraging results in elderly patients with EGFR NSCLC. The efficacy and safety profile of aumolertinib was similar in both younger and older patient subgroups. These findings suggest that aumolertinib may be a viable treatment option for elderly patients with EGFR NSCLC.

Asset Subtitle

Shencun Fang

Meta Tag

Speaker Shencun Fang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

first-line therapy

elderly patients

epidermal growth factor receptor

non-small cell lung cancer

EGFR-tyrosine kinase inhibitors

organ function

multiple diseases

efficacy

safety